(Q36341551)

13 August 2017

1 reference

title

Neoadjuvant chemotherapy for oesophageal cancer: the need for accurate response prediction and evaluation (English)

1 reference

13 August 2017

Forshaw MJ

1

1 reference

13 August 2017

Gossage JA

series ordinal

2

1 reference

13 August 2017

Mason RC

series ordinal

3

1 reference

13 August 2017

publication date

1 December 2005

1 reference

Journal of the Royal College of Surgeons of Edinburgh

13 August 2017

published in

1 reference

13 August 2017

volume

3

1 reference

13 August 2017

issue

6

1 reference

13 August 2017

page(s)

373-82, 422

1 reference

Estimates of the worldwide mortality from 25 cancers in 1990.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Recent changes in the epidemiology of esophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Esophageal surgery at the end of the millennium

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Multidisciplinary approach to esophageal and gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Multimodality therapy for resectable cancer of the thoracic esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Treatment of esophageal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Preoperative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Is esophageal cancer a surgical disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Cancer of the esophagus and gastro-esophageal junction: potentially curative therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Cancer of the esophagogastric junction

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Micrometastases in esophagogastric cancer: high detection rate in resected rib segments.

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Predictive factors for success of neo-adjuvant therapy in upper gastrointestinal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Neoadjuvant therapy for oesophagogastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Early impact of centralization of oesophageal cancer surgery services.

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Cohort study in South and West England of the influence of specialization on the management and outcome of patients with oesophageal and gastric cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Effect of surgical experience on the results of resection for oesophageal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Surgical workload and outcome after resection for carcinoma of the oesophagus and cardia

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Influence of clinician workload and patterns of treatment on survival from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Survival outcome of care by specialist surgeons in breast cancer: a study of 3786 patients in the west of Scotland

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Medical audit, cancer registration, and survival in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Hospital volume and hospital mortality for esophagectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Outcomes after esophagectomy: a ten-year prospective cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Cervical esophagogastric anastomosis: results following esophagectomy for carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Treatment of carcinoma of the esophagus or cardia

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Postoperative mortality following oesophagectomy and problems in reporting its rate.

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Treatment outcomes of resected esophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Induction chemotherapy in the treatment of patients with carcinoma of the esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Does preoperative chemotherapy cause adverse effects on the perioperative course of patients undergoing esophagectomy for carcinoma?

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Weight gain as an indicator of response to chemotherapy for oesophageal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Endoscopic ultrasonography for assessment of the response to combined radiation therapy and chemotherapy in patients with esophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037)

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Epirubicin, cisplatin, and fluorouracil in gastric and esophageal cancer: a step ahead?

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Endoscopic ultrasonography in the staging of esophageal carcinoma after preoperative radiotherapy and chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Evaluation of Response to Neoadjuvant Therapy by Quantitative 2-Deoxy-2-[F]Fluoro-D-Glucose with Positron Emission Tomography in Patients with Esophageal Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Molecular biology of upper gastrointestinal malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Histological response of cisplatin predicts patients' survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus.

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

Positron emission tomography/computerized tomography functional imaging of esophageal and colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1479-666X%2805%2980047-2

7 January 2021

10.1016/S1479-666X(05)80047-2

Identifiers

DOI

1 reference

13 August 2017

1 reference